Innovative Industrial Properties Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Innovative Industrial Properties Inc trades at $51.47 (market cap $1.42B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 6.2× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 14.74% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innovative Industrial Properties Inc for 87 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| IIPR | KYMR | |
|---|---|---|
Market Cap | $1.42B | $8.87B |
Volume | 427,967 | 779,107 |
Sector | Real Estate | Health |
52-Week High | $64.67 | $127.31 |
52-Week Low | $44.58 | $55.80 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $1.95B | $8.26B |
Dividend Yield | 14.74% | — |
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $51.43, up 0.47% on the day, exhibiting a bearish technical trend near key support at $51. Fundamentally, the REIT shows high gross margins of 88.35% but faces revenue and net income declines in 2025. Recent news highlights a significant $245 million mezzanine loan commitment, signaling active capital deployment despite sector headwinds.
The outlook is mixed; the stock offers a high dividend yield but carries risks from tenant defaults and volatile earnings. Analyst consensus is cautious with a majority Hold rating. Investors should weigh the attractive valuation metrics against operational challenges in the cannabis real estate sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →